替莫唑胺
医学
神经内分泌肿瘤
垂体瘤
垂体腺瘤
肿瘤科
病理
内科学
腺瘤
生物信息学
生物
化疗
出处
期刊:Endocrine Journal
[The Japan Endocrine Society]
日期:2023-01-01
卷期号:70 (3): 241-248
被引量:3
标识
DOI:10.1507/endocrj.ej23-0007
摘要
The majority of anterior pituitary tumors behave benignly, that is, they grow slowly and do not metastasize, and were therefore called adenomas. However, they would frequently invade adjacent structures, leading to recurrence. One of the misleading assumptions in their previous classification was the simplistic distinction made between adenoma and carcinoma. In the upcoming WHO 2022 classification, a new terminology will be introduced: pituitary neuroendocrine tumor (PitNET) which is consistent with that used for other neuroendocrine neoplasms. In general, aggressive PitNETs are invasive and proliferative tumors with frequent recurrences, resistant to conventional treatments, and yet virtually without metastases. At present, no single morphological or histological marker has been shown as yet to reliably predict their aggressive behavior. In terms of treatment, temozolomide (TMZ) had been considered promising and the sole therapeutic option for aggressive and malignant PitNETs following failure of standard therapies. However, recent reports have disclosed that TMZ does not provide long-term control of many aggressive PitNETs. A further multidisciplinary approach is necessary for both reliable prediction and successful management of aggressive PitNETs.
科研通智能强力驱动
Strongly Powered by AbleSci AI